Understanding the molecular mechanism of action of Lenalidomide in Multiple Myeloma

A 60-year-old woman who was diagnosed with multiple myeloma undergoes induction therapy with Bortezomib-Lenalidomide-Dexamethasone (RVD) induction regimen. This is followed by successful high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) combined with bortezomib. Maintenance therapy with lenalidomide is now initiated.

Which of the following statements best describes the molecular mechanism of action of this drug in the treatment of this condition?